Skip to main navigation

Overview
News & Events
Stock
Governance
Financials
IR Resources
Stock Feed

Investor Relations

Latest Earnings Latest Annual Report

Overview

Tenax Therapeutics is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies.

News Releases

Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

September 1, 2026

Read More

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026

August 29, 2026

Read More

Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

August 10, 2026

Read More

All News Releases

Corporate Presentation

Corporate Presentation July 2026

Q2 2026 Results

Earnings Release
Form 10-Q

All Quarterly Results

Events

Upcoming Events

2026 Cantor Global Healthcare Conference

September 9, 2026 8:35 AM EDT

Past Events

Tenax Therapeutics Phase 3 LEVEL Topline Results

August 10, 2026 8:00 AM EDT

Past Events

2026 Leerink Partners Global Healthcare Conference

March 10, 2026 2:20 PM EDT

Past Events

Guggenheim Emerging Outlook: Biotech Summit 2026

February 11, 2026 12:30 PM EST

All Events

Investor Contact

Argot Partners

draftstenax@argotpartners.com

phone_iphone +1 212-600-1494

Subscribe to our Email Alerts

Email Address Required

© Tenax Therapeutics

|

Site Map

Search Investors

Search this site